BioCentury | Apr 9, 2021
Deals

April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M

Women’s health company Hologic Inc. (NASDAQ:HOLX) is acquiring Mobidiag Ltd., a Finnish-French maker of molecular diagnostics and instruments, for about $795 million, including $741 in cash and the assumption of net debt of about $81...
BioCentury | Jan 9, 2021
Finance

4Q20 Wrap: Stocking up

Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way through early-stage trials. IRAK4 mediates innate...
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche indications where it believes the product can help dysfunctional...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

Amgen readies sotorasib for FDA  Amgen Inc. (NASDAQ:AMGN) said it plans to submit an NDA for its closely watched KRAS inhibitor sotorasib by year-end to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C...
BioCentury | Dec 4, 2020
Distillery Therapeutics

Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies

DISEASE CATEGORY: Musculoskeletal; ophthalmic disease INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has designed an RNA-targeting small molecule that could treat DM1 and Fuchs...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

In the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy test, growing the number of genetic biomarkers indicated for matching patients to targeted therapies. The...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...
Items per page:
1 - 10 of 2349